Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq differences between patients with ulcer pressures grade II vs patients with ulcer pressures grade III-IV

ABSTRACT: RNA-seq differences between patients with ulcer pressures grade II vs patients with ulcer pressures grade III-IV

PROVIDER: PRJNA957767 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24226271.fastq.gz	Fastqsanger.gz
	SRR24226272.fastq.gz	Fastqsanger.gz
	SRR24226273.fastq.gz	Fastqsanger.gz
	SRR24226274.fastq.gz	Fastqsanger.gz
	SRR24226275.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

RNA-seq differences between patients with ulcer pressures grade II vs patients with ulcer pressures grade III-IV

Project description:we want to find those markers and pathways that differ between patients with ulcer pressures grade II (less severe) than patients with ulcer pressures grade III-IV (severe)

2025-06-02 | GSE230161 | GEO

Transcription profiling of human grade II astrocytic tumor (astrocytomas) vs grade IV tumors (glioblastoma)

Project description:Comparison of grade II astrocytic tumor (astrocytomas) with grade IV tumors (glioblastoma)

2007-03-01 | E-MEXP-567 | biostudies-arrayexpress

Genome-wide analysis of mRNA expression alterations in Stage III-IV high-grade serous ovarian cancer patients exhibiting clinically defined differences in ascites volume (high volume ascites versus low volume ascites)

Project description:Microarrays were used to examine gene expression changes in the surgical resections of high-grade serous ovarian cancer patients exhibiting clinically distinct levels of ascites volume. The present studies primary aim was to determine if there is a molecular gene expression difference between the patients presenting at time of surgery when high volumes ascites cases were compared to those with low volume ascites. The secondary aim was to determine what relevance this difference, if found, has to previously discovered molecular sub-types of high grade serous ovarian cancer. Total RNA obtained from snap-frozen stage III-IV high-grade serous ovarian cancer patients presenting with low volume (<=200 cc) or high volume (>=1000 cc) ascites volume.

2014-10-01 | E-GEOD-51831 | biostudies-arrayexpress

Genome-wide analysis of long noncoding RNA expression profile in patients with Marjolin’s ulcer

Project description:Marjolin’s Ulcer is an aggressive cutaneous malignancy that typically ensues over a period of time in the post-burned lesions and scars or any other chronic wound. Marjolin’s Ulcer makes up 1.2% of all skin cancers, it is reported that 2% of squamous cell carcinoma and 0.03% of basal cell carcinoma originate in burn scars. Recent studies have shown that long non-coding (lncRNA) plays critical roles in a myriad of biological processes and human diseases,Since the roles of lncRNA in Marjolin’s Ulcer remain unknown,they were investigated in the study.Our findings indicate that the expression profiles of lncRNAs has changed in Marjolin’s Ulcer as compared with normal skin and para-cancerous scar, and may provide novel insight into the molecular mechanism underlying the disease and potential novel diagnostic or therapeutic targets for Marjolin’s Ulcer.

2018-12-11 | GSE110138 | GEO

iTRAQ-based quantitative proteomic analysis of nuclear fractions of glioma (WHO grade II, III and IV) tissues to identify altered transcriptional regulatory proteins

Project description:Glioma tumors arise from normal glial cells (astrocytes). Gliomas are morphologically and clinically classified into four malignancy grades as Grade I, II, III and IV. Grade I and II comprise low grade gliomas that grow slowly, are well differentiated and have a better prognosis and survival compared to grades III and IV. In contrast, grade III-IV lack endothelial proliferation and are highly vascular with a tendency to infiltrate and have areas of extensive necrosis and hypoxia. In the present study, we used iTRAQ (isobaric tags for relative and absolute quantitation) - based quantitative proteomic approach followed by online liquid chromatography and high resolution tandem mass spectrometry (LC-MS/MS) to identify differential nuclear proteins enriched with transcriptional regulatory function from three different grades of astrocytoma tumors (WHO Grade II, III and IV) compared to control.

2019-08-06 | PXD014111 | Pride

Immunologic adapatations of high grade serous ovarian cancer patients to neoadjuvant carboplatin and paclitaxel therapy

Project description:770 genes as well as pathways and deconvoluted immune cell types were determined pre- and post-neoadjuvant chemotherapy in a cohort of 31 stage III-IV high grade serous ovarian cancer (HGSOC) patients, and associations were made with the duration of their platinum-free interval n/a

2022-09-28 | GSE201600 | GEO

Transcriptomics in whole-blood cells of Buruli ulcer patients identifies a signature of inflammation

Project description:Mycolactone, a lipid-like toxin, is the major virulence factor of Mycobacterium ulcerans, the etiological agent of Buruli ulcer. Its involvement in lesions development has been widely described in early stages of the disease, through its cytotoxic and immunosuppressive activities, but less is known about later stages. Here, we revisit the role of mycolactone in disease outcome and provide the first demonstration of the pro-inflammatory potential of this toxin. We found that the mycolactone-containing mycobacterial extracellular vesicles produced by M. ulcerans induced the production of IL-1β, a potent pro-inflammatory cytokine, in a TLR2-dependent manner, targeting NLRP3/1 inflammasomes. We showed our data to be relevant in a physiological context. The in vivo injection of these mycolactone-containing vesicles induced a strong local inflammatory response and tissue damages, which were prevented by corticosteroids. Finally, several soluble pro-inflammatory factors, including IL-1β, were detected in infected tissues from mice and Buruli ulcer patients. Our results revisit Buruli ulcer pathophysiology by giving a new insight, thus paving the way for development of new therapeutic strategies, taking account the pro-inflammatory potential of mycolactone.

2020-12-29 | GSE157350 | GEO

Gastric ulcer mice gastric tissue

Project description:Indomethacin was applied to establish a mice model of gastric ulcer, 24 h later, gastric tissue were obtain

2025-05-07 | PXD058482 | Pride

Gene expression of ulcer-associated cell lineage

Project description:We applied RNA-seq analysis of total RNA isolated from laser capture microdissected intestinal epithelium. The analysis aimed at charactericing the gene expression seen in ulcer-associated cell lineage epithelial cells, and to contrast this with that of healthy control epithelium and epithelium from inflammatory bowel disease-patients with active inflammation.

2019-04-01 | GSE126299 | GEO

iTRAQ-based quantitative proteomic analysis of membrane and nuclear fractions of glioma (WHO grade II, III and IV) tissues to map on Chromosome 12 and identification of mass spectrometry evidence for 'missing proteins'

Project description:Glioma tumors arise from normal glial cells (astrocytes). Gliomas are morphologically and clinically classified into four malignancy grades as Grade I, II, III and IV. Grade I and II comprise low grade gliomas that grow slowly, are well differentiated and have a better prognosis and survival compared to grades III and IV. In contrast, grade III-IV lack endothelial proliferation and are highly vascular with a tendency to infiltrate and have areas of extensive necrosis and hypoxia. In the present study, we used iTRAQ (isobaric tags for relative and absolute quantitation) - based quantitative proteomic approach followed by liquid chromatography and high resolution tandem mass spectrometry (LC-MS/MS) to identify differential membrane and nuclear proteins mapping to Chromosome 12 from three different grades of astrocytoma tumors (WHO Grade II, III and IV) compared to control.

2019-06-04 | PXD000848 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data